Tests urine samples for signs of bladder and kidney cancer
Checks DNA and proteins in urine to help detect urothelial cancer in adults.
Key facts
- Who runs it
- Lahey Clinic
- Where
- Burlington, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- Sept 2002
- Expected to end
- Nov 2028
- Type of study
- Observational, 2 groups
- Record updated
- 8 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are scheduled for bladder or kidney cancer surgery or a bladder exam, and for adults with no known bladder cancer who give one urine sample as a control group.
- Age
- Older than 18 years
- Sex
- All sexes
- Disease stage
- Newly diagnosed bladder cancer, or bladder cancer that has come back and is being followed up. A control group has no known bladder cancer.
Main reasons for not taking part
- Younger than 18 years of age
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up)
- Control Group: No known evidence of bladder cancer-one urine sample
- > than 18 years of age
Who cannot take part
- < than 18 years of age
Where in United States
- Lahey Clinic, IncBurlington, United StatesContact: Arthur Mourtzinos, M.D. (sub-investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission and recurrence
The 2 groups in the trial
- 1
Bladder Cancer Group: Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue. Two urine samples collected at the time of the scheduled procedure: One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection.
- 2
Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
- Plain-language title
- Tests urine samples for signs of bladder and kidney cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 December 2025